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Available online 9 January 2016Alzheimer's disease is the prevalent cause of premature senility, a progressive mental disorder due to degeneration
in brain and deposition of amyloid β peptide (1–42, amisfolded protein) in the form of aggregation that prevails for
a prolonged time and obstructs every aspect of life. One of the primary hallmarks of the neuropathological disease is
the accretionof amyloidβpeptide in the brain that leads toAlzheimer's disease, but themechanism is still amystery.
Several investigations have shown that mutations at speciﬁc positions have a signiﬁcant impact in stability of the
peptide as predicted from aggregation proﬁles. Here in our study, we have analyzed the mutations by substituting
residues at position A22G, E22G, E22K, E22Q, D23N, L34V and molecular dynamics have been performed to check
the deviation in stability and conformation of the peptide. The results validated that the mutations at speciﬁc posi-
tions lead to instability and the proline substitution at E22P and L34P stalled the aggregation of the peptide.








Discovery Studio Visualizer1. Introduction
Alzheimer's disease is a neurodegenerative disorder that affects
the brain with a continuous loss of memory and inability to respond to
stimuli that causes dementia that is most common in old-age people
(above 65 years) with late-onset and less common in childhood (before
65 years) with early onset, classiﬁed as two stages, respectively [1,2]. The
disorder prevails for a prolonged time and loss of memory worsens,
which obstructswith every aspect of daily lives. Personality and behavioral
changes affect the social aspects by trouble in interactingwith the social en-
vironment [5,6]. Agitation, withdrawal, and appropriate loss of memory
and skills are the common symptoms that lead tomortality due to other in-
fections like pneumonia, malnutrition, etc., accounting for less than 5% in
early-onset cases [3]. The gene responsible for the disease is APP, which
provides instructions formaking aprotein called amyloid precursor protein
found in brain and spinal cord. Though researchers contemplate that itmay
bind to several other proteins on the surface of the cells or help cells attach
to one another, themechanism and pathogenesis is still amystery [4]. Sev-
eral enzymes cut the amyloid precursor protein into two smaller fragments
or peptides amyloid precursor protein (APP) and amyloidβ peptide,which
are released outside the cell. Amyloid β peptide is likely involved in the
ability of neurons to change and adapt over time (plasticity) [7,9,10]..
. This is an open access article underThemutation in the APP gene is responsible for the same accounting
for more than 50 different types of mutations [8], which lead to early
and late onset of the disease, some of which are discussed later. The
most commonmutation is V717I (as seen in Fig. 2) that leads to amyloid
β aggregation in the brain and forms clumps called amyloid plaques thus
releasing β amyloid peptides of 40, 42, 43 residue Aβ peptides. Six
mutations in the APP gene have been found to cause hereditary cerebral
amyloid angiopathy [13,14], a condition characterized by stroke and a
decline in intellectual function (dementia), which begins in mid-
adulthood [15,16]. The Dutch type, the most common of all the types,
is caused by the replacement of the amino acid glutamic acid with the
amino acid glutamine at position 22 in the protein sequence (Glu22Gln
or E22Q). The Italian type and Arctic type are also caused by changes to
glutamic acid at position 22. In the Italian type, glutamic acid is replaced
with the amino acid lysine (Glu22Lys or E22K), and in the Arctic type,
glutamic acid is replaced with the amino acid glycine (Glu22Gly or
E22G). The Flemish type is caused by replacement of the amino acid al-
anine with glycine at position 21 (Ala21Gly or A21G). In the Iowa type,
the amino acid aspartic acid is switched with the amino acid asparagine
at position 23 (Asp23Asn or D23N). The Piedmont type of hereditary ce-
rebral amyloid angiopathy is caused by the replacement of the amino
acid leucine at position 34 with the amino acid valine (Leu34Val or
L34V). These mutations lead to aggregation and deposition of amyloid
β peptide (1–42) in the brain that are prone to form clusters and accu-
mulate in blood vessels known as plaques thus lead to dementia [9–12].the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Disorders due to Alzheimer's disease—Weizmann Institute of science [17].
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lecular dynamics simulation using NAMD and their deviation (RMSD)
was analyzed and plots were generated using chimera. The mutations
lead to the formation of β ﬁbril (Alpha helix converted to β sheets) that
were predicted using PASTA2.0 and stability of the mutated peptides
were analyzed using mutational analysis tools [29] like PolyPhen 2.0
and I-Mutant 3.0 in comparison to wild type amyloid β peptide (1–42).
2. Materials and methods
2.1. Retrieval of protein structure
The structural analysis of amyloid β (1–42) has been retrieved from
the largest structure repository Protein Data Bank (PDB) having PDB-ID
1IYT [18] (solution structure of the Alzheimer's disease amyloid βFig. 2. The most common mutation
Table 1
Mutational analysis.
S. no. Residue position Mutated positions Type of mutation
1 21 Ala21–Gly21 Flemish type
2 22 Glu22–Gly 22 Arctic type
3 22 Glu22–Lys22 Italian type
4 22 Glu22–Gln22 Dutch type
5 23 Asp23–Asn23 Iowa type
6 34 Leu34–Val34 Piedmont typepeptide (1–42)(Fig. 1). The structure has been subjected to mutational
analysis computationally and employed as commencement for molecu-
lar dynamics. The sequential perspective to study the amino acid residual
substitution, signiﬁcant mutagenesis, and other functionality was
derived from UniprotKB [19] having accession no. P05067 in amyloid
β peptide (1–42). Other variants of amyloid β peptides like amyloid
β ﬁbrils (PDB-ID-2BEG) have also been retrieved to study the bonding
patterns formed due to aggregation of the peptide in Alzheimer's
disease.
2.2. Mutations and energy calculation
As per the literature review, the amyloid β peptide (1–42) was
subsequently mutated at residual positions 21, 22, 23, and 34 using
Swiss PDB Viewer [20] to understand the effects, i.e. stability on the
peptide during aggregation. The energy force ﬁeld of the wild type
structure, mutated structures was calculated using default parameters.
The energy minimization of the wild type as well as the mutated
structures was done using steepest descent algorithm with a cutoff of
10 angstrom to check the proportionality of bond angles, improper,
torsions, electrostatic bonds. Signiﬁcant differences have been observed
which state the stability of the mutated proteins as compared to the
wild type. The stability of the protein is signiﬁcantly reduced when
the energy has been computed using UFF force ﬁelds using Swiss PDB
viewer as seen in (Table 1). It has been observed that the wild type
protein energy when compared to the mutated sites, respectively, is
having least energy conformation.in amyloid β peptide (1–42).







Fig. 3. Amyloid ﬁbril formation due to aggregation of β sheets joined by a hinge.
Fig. 4. a)Probable regions predicted. b) Probability of aggregat
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The aggregation of the amyloid β peptide was experimentally
determined, which is the main cause of Alzheimer's disease. For the
better understanding of the aggregation process from amino acid
sequence of the structure, PASTA [21] (prediction of amyloid structure
aggregation) was used that determines the portion of the sequence
involved in aggregation with graphical interface, which is more likely
to stabilize the cross-β core of ﬁbrillar aggregates as shown in (Fig. 3).
The server also provides intrinsic disorder and secondary structure
predictions that complement the aggregation data.
3. Mutational analysis
3.1. I-Mutant 3.0 and PolyPhen 2.0
The Genetics Home Reference fromU.S National Library of Medicine
gives a detailed functional and structural aspect of the amyloid β
precursor protein that elucidates the pathogenesis caused by mutation
in speciﬁc positions as mentioned above. To have a better insight toion. c)Aggregation helix, free energy, and disorder proﬁle.
Table 2
RMSD deviation plot and map of all positional speciﬁc mutation in comparison to wild
type.
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I-Mutant 3.0 [22] did analysis where a single-point mutation may lead
to several chronic diseases. The study of the effect of a mutation may
alter the stability and might lead to pathogenicity as previously
reported. PolyPhen-2 (Polymorphism Phenotyping v2) [23] is a tool
which predicts possible impact of an amino acid substitution on the
structure and function of human proteins that describe the non-
synonymous SNP effect. Thus, to analyze the effects of mutation, this
tool has been used to encode the damaging effect determined by its
sensitivity and speciﬁcity score.
3.2. Molecular dynamics
Molecular dynamics simulation has emerged as a vital aspect to
interpret the intrinsic molecular aspects of several proteins. The state
of experimental methodologies has been simpliﬁed by simulation
approach as it reveals the mechanism involved in atomistic level of
the protein. Here in our study, the molecular dynamics simulation
approach has been applied to study the stability aspect of our wild
and mutated proteins in amyloid β peptide (1–42). For the purpose to
identify the effects of mutations, the mutated and wild type proteins
were subjected to Scalable Molecular Dynamics NAMD [24] software
from Theoretical Biophysics Group, University of Illinois and Beckman
Institute, which is a command line program interpreted and altered by
Visual Molecular Dynamics [25] (VMD) program.
3.3. Types of mutations
The pathogenesis of AD is a hypothesis, which is supported by
detailed evidence that argues the accumulation and aggregation of
amyloid β peptide. Several missense mutations support the fact that
the change in the amino acids leads to onset of AD. The primary
references of amyloid precursor protein mutations have been reported
earlier since from 1990, soon after the description of pathology of AD
by German psychiatrist and near pathologist Alois Alzheimer in 1906
[32]. The common type of mutations are Swedish (1992), Flemish
(1992), Dutch (1990), Arctic (2001), Italian (2010), Osaka (2008),
Iowa (2001), Austrian (2000), Iranian (2002), French (1999), German
(2001), Florida (1997), London (1991), Indiana (1991), and Australian
(2000). Experimental evidence by NMR studies identiﬁed that a
mutations at position E22 and D23 mutations destabilize this turn of
the region V24 to K28 (Fig. 6) and thereby promote oligomer formation
that results in aggregation [30,31].
4. Results
The amyloid structure aggregation prediction that is a resultant of β
sheets from helix stabilized residues in secondary structure conforma-
tion was the main viewpoint in this work which was done by using
PASTA 2.0. The graphical plots generated thus imply that the residues
ranging from 32 to 40 assumed to attain β sheet conformation,
i.e. β-amyloid regions. The graph illustrates the parallel aggregation
proﬁle in residual range of 32–40. Aggregation free energy proﬁle
and strand proﬁle predicted from the server shows that the residues
belonging to the residual range 32–40 for formation of aggregates
were below the threshold value, which clearly shows the instability
index and aggregation of amyloid regions as shown in (Fig. 4a, b, c).
5. Dynamics
To study the behavioral and stability aspect of the residues and their
conformations due to mutations in protein through MD simulation
which depict the intrinsic molecular aspect in atomistic level. The mu-
tated proteins as well as the wild type protein were subjected to VMD
for protein structure ﬁles generation (PSF), which is a prerequisite for
NAMD simulation. The minimization and equilibration of the proteinswere done using several parameters. The temperature was set to
310 K with CHARMM force ﬁeld parameter and integrated time step.
i.e. 2 fs/s. The peptide was cantered in a cubic simulation box with a
1 nm distance allowed between the peptide and the edges of the box
treated with periodic boundary conditions where it shows the stability
of a protein inside a solvent box in which the deviation in the RMSD can
be analyzed. LANGEVIN Temperature that is a default parameter in
conﬁguration ﬁle and PME (for full-system periodic electrostatics)
were set to 175 during parameterization. The restart frequency was
set to 500 steps for every 1 ps. The minimization and dynamics was
done for 10 ps with a frame rate of 1100 that plots a deviation
(RMSD) in which the stability of the proteins was analyzed as shown
in (Table 2).
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The conformation of amyloid β peptides consists of two α-helical
regions that exist at residues 8–25 and 28–38. Other residues apart
from the alpha helical regions acquire the coil conformation. Proline
acts as a β sheet breaker, which is most common in amyloid β ﬁbrils,
that attains a conformation in diseased condition [28]. Insertion of
bulky groups or proline within the β sheet regions is effective in inhibi-
tion of aggregation as shown in Fig. 5h).
6. Discussion
The current work was intended at understanding the effects of
mutation and substitution of amyloid β peptide in aggregation. The
amyloid β ﬁbril formation is the main cause in Alzheimer's disease
that is pointedly related to its pathogenesis. The types of mutations as
reported in literature review have been done using Swiss PDB Viewer
at speciﬁc positions like A22G, E22G, E22K, E22Q, D23N, L34V in
amyloid β peptide (1–42) as shown in (Fig. 6) and were subjected to
molecular dynamics using NAMD and VMD. Signiﬁcant changes wereFig. 5. Diagrammatic representation of position speciﬁc mobserved using UCSF Chimera [27] by the means of RMSD deviation
plots and maps, inclining toward the stability effect and chance of
formation of amyloid ﬁbrils (β sheets rich conformations) in AD.
Despite that the role of amyloid β peptide in formation of β
sheet conformations due to aggregation is revealed, the actual
mechanism is a mystery. The aggregation proﬁle plots generated
by PASTA 2.0 server implies the probability of formation of β
sheets at helix positions in the peptide, i.e. (21–42) which clearly
indicates that mutational changes affect the helix conformation and
subsequently leads to formation of β sheets in due time intervals that
is achieved by the RMSD deviation plots generated and simulation
approach. The different types of mutations reported were done and
their stability were analyzed using I-Mutant 3.0 and PolyPhen2.0
which shows signiﬁcant decrease in its stability upon mutation. L34V
was considered as the common mutation as shown in (Fig. 2), which
shows a signiﬁcant variation as compared to wild type amyloid β
peptide (1–42). The substitution of proline that acts as a β sheet breaker
were substituted at position E22P and L34P as it provides a link at
particular site that further prevents the formation of β sheets (β ﬁbril
conformation).utation using Discovery Studio Visualizer 4.1 [26].
Fig. 6.Mutation types at speciﬁc positions in amyloid β peptide.
194 P.K. Panda et al. / Genomics Data 7 (2016) 189–1947. Conclusion
The pathogenesis of AD is still clandestine, as the mechanism of
formation of β sheet conformation as a result of aggregation is not yet
understood. The mutation at speciﬁc positions leads to instability of
peptides as seen in (Tables 1 and 2). Due to substitution of proline, the
signiﬁcant proportionality in reduction of aggregation was observed as
it acts as a β sheet breaker. Since the changes observed due to different
types of mutations were signiﬁcant by means of molecular dynamics
and the study might lead to understanding of the pathogenesis of AD.
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